Drug Combination Details
| General Information of the Combination (ID: C22519) | |||||
|---|---|---|---|---|---|
| Name | Epigallocatechin gallate NP Info | + | 5-fluorouracil Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [1] | ||
|
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [2] | |||
|
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [3] | |||
|
Colon cancer
[ICD-11: 2B90]
|
Investigative | [3] | |||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [3] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HSPA5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | microRNA 155 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| DLD-1 | CVCL_0248 | Colon adenocarcinoma | Homo sapiens | |||
| In-vivo Model | DLD1 (1*106) cells were injected subcutaneously into female BALB/c nude mice. | |||||
| Experimental
Result(s) |
(-)-Epigallocatechin gallate (EGCG) enhances the sensitivity of colorectal cancer cells to 5-FU by inhibiting GRP78/NF-kappaB/miR-155-5p/MDR1 pathway. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| BxPC-3 | CVCL_0186 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
| HCT 15 | CVCL_0292 | Colon adenocarcinoma | Homo sapiens | |||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| NCI-H358 | CVCL_1559 | Lung adenocarcinoma | Homo sapiens | |||
| A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
EGCG sensitizes 5FU-induced cytotoxicity by targeting the ERK pathway in multiple cancer cell lines. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TFAP2A | Molecule Info | |||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | ||
| MGC-803 | CVCL_5334 | Gastric mucinous adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Exponentially growing SCG7901/FU cells (5*106) were injected subcutaneously into the dorsum of female BALB/c nude mice. | |||||
| Experimental
Result(s) |
Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer. | |||||
